Plis enfomasyon ― Kreyòl ayisyen

Urticaria a souvan prezante ak gratèl entans ki soulve welts. Li pafwa akonpaye pa anfle nan tisi ki kache yo. Tretman prensipalman enplike evite deklanche, si yo konnen yo. Medikaman premye liy gen ladan nouvo antihistamine, ki ka ogmante dòz si sa nesesè. Lòt medikaman tankou antihistamine ki pi gran, H2 blocker, leukotriene receptor antagonist, antihistamine pi fò, ak kout tèm kortikoterapi ka ajoute kòm sipò siplemantè. Nan ka kote urtikè a pèsiste malgre mezi sa yo, pasyan yo ka refere yo bay espesyalis pou terapi adisyonèl tankou omalizumab oswa cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Revizyon sa a eksplike dènye direktiv yo pou trete urtikarya epi li ofri nouvo konpreyansyon sou kòz li.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids